

Charles M. Lizza  
William C. Baton  
Sarah A. Sullivan  
SAUL EWING ARNSTEIN & LEHR LLP  
One Riverfront Plaza, Suite 1520  
Newark, NJ 07102-5426  
(973) 286-6700  
clizza@saul.com

*Attorneys for Plaintiffs  
Mitsubishi Tanabe Pharma Corp.,  
Janssen Pharmaceuticals, Inc., Janssen  
Pharmaceutica NV, Janssen Research  
and Development, LLC, and Cilag  
GmbH International*

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

MITSUBISHI TANABE PHARMA  
CORPORATION, JANSSEN  
PHARMACEUTICALS, INC., JANSSEN  
PHARMACEUTICA NV, JANSSEN  
RESEARCH AND DEVELOPMENT, LLC,  
and CILAG GMBH INTERNATIONAL,

Plaintiffs,

v.

SANDOZ INC., *et al.*,

Defendants.

**Civil Action No. 17-5319 (FLW)(DEA)  
(consolidated)**


**ORDER**

**(Filed Electronically)**

This matter having come before the Court by a stipulation between Plaintiffs Mitsubishi Tanabe Pharma Corp., Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, Janssen Research and Development, LLC, and Cilag GmbH International (collectively, "Plaintiffs") and Defendant Zydus Pharmaceuticals (USA) Inc. ("Zydus"); and the Court having considered the stipulation and the provisions set forth therein; and for good cause shown,

IT IS ON THIS 24th day of April, 2020,

ORDERED that the statutory stay of U.S. Food and Drug Administration (“FDA”) approval of Zydus’s ANDA Nos. 210541 and 210542 is hereby extended from September 29, 2020, until one-hundred and twenty (120) days from the conclusion date of the trial in the above-captioned action. Zydus shall notify the FDA of this Order within five business days after its entry by the Court. Zydus shall further notify the FDA of the conclusion of the trial within five business days after the conclusion date.

  
\_\_\_\_\_  
Hon. Freda L. Wolfson, U.S.D.J.